I'm Camila, not only CEO of MediOwl, but also a rheumatism patient. Worldwide, 420 million people suffer from various inflammatory diseases, but we all face the same problem: uncertainty. This is overwhelming and powerless.
At MediOwl, we develop monitoring devices for patients with chronic inflammation. Our all-in-one solution provides clinicians with insights to better monitor their patients and enables patients to effectively manage their condition. At MediOwl, we don't just offer patients devices; we offer them a toolkit to regain control of their lives.
If you know any rheumatologists who might be interested in our study, please tell them about our Owl Eyes and our goal to see patients progress.
